

Systematic review and network meta-analysis comparing prevention of stroke and major bleeding in patients with

BMJ Open

4, e004301-e004301

DOI: [10.1136/bmjopen-2013-004301](https://doi.org/10.1136/bmjopen-2013-004301)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bleeding complications of targeted oral anticoagulants: what is the risk?. Hematology American Society of Hematology Education Program, 2014, 2014, 504-509.	0.9	12
2	Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. Journal of Cardiovascular Medicine, 2014, 15, 873-879.	0.6	36
3	Intracranial Hemorrhage Caused by Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) – A Multicenter Retrospective Cohort Study in Japan. Circulation Journal, 2015, 79, 1018-1023.	0.7	32
4	Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety, 2015, 24, 757-764.	0.9	22
5	Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0142222.	1.1	9
6	Antithrombotic treatment in elderly patients with atrial fibrillation. Revista Clínica Española, 2015, 215, 171-181.	0.3	3
7	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal. Cost-effectiveness of new oral anticoagulants in Portuguese atrial fibrillation patients. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 723-737.	0.2	5
9	Custo-efetividade dos novos anticoagulantes orais na fibrilhação auricular em Portugal. Revista Portuguesa De Cardiologia, 2015, 34, 723-737.	0.2	11
10	Tratamiento antitrombótico en el paciente anciano con fibrilación auricular. Revista Clínica Española, 2015, 215, 171-181.	0.2	15
11	Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. International Journal of Cardiology, 2015, 184, 772-795.	0.8	15
12	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2015, 13, 1155-1163.	0.6	1
13	Edoxaban: A Review in Nonvalvular Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2015, 15, 351-361.	1.0	5
14	The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Annals of Internal Medicine, 2015, 162, 777-784.	2.0	4,590
15	Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis. Journal of the American Medical Directors Association, 2015, 16, 1103.e1-1103.e19.	1.2	40
16	Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. Expert Opinion on Drug Safety, 2015, 14, 7-20.	1.0	23
17	Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAf) in the US. ClinicoEconomics and Outcomes Research, 2016, 8, 215.	0.7	18
18	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 93-107.	0.8	35
19	Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. International Journal of Cardiology, 2016, 220, 794-801.	0.8	20

#	ARTICLE	IF	CITATIONS
20	Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. <i>Thrombosis Research</i> , 2016, 145, 143-148.	0.8	16
21	Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. <i>European Journal of Epidemiology</i> , 2016, 31, 541-561.	2.5	21
22	Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. <i>The Cochrane Library</i> , 2016, , .	1.5	3
24	Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 218, 235-239.	0.8	5
25	Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	55
26	Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, s14-s26.	0.5	15
27	Patient preference and evidence based decisions on anticoagulant therapy for atrial fibrillation. <i>Thrombosis Research</i> , 2016, 145, 149-150.	0.8	0
28	Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2272-2283.	1.2	64
30	Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. <i>Europace</i> , 2016, 18, 1507-1513.	0.7	7
31	Brain embolism. , 0, , 312-363.		1
32	Spontaneous Intracerebral Hemorrhage Due to Coagulation Disorders. , 2016, , 309-316.		0
33	Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the "Optimal" Oral Anticoagulant for Atrial Fibrillation. <i>Value in Health</i> , 2016, 19, 661-669.	0.1	3
34	Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. <i>European Heart Journal</i> , 2016, 37, 2455-2464.	1.0	29
35	Prolonged Cardiac Monitoring to Detect Atrial Fibrillation after Cryptogenic Stroke or Transient Ischemic Attack: A Meta-Analysis of Randomized Controlled Trials. <i>Annals of Noninvasive Electrocardiology</i> , 2016, 21, 382-388.	0.5	23
36	Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. <i>International Journal of Cardiology</i> , 2016, 204, 88-94.	0.8	73
37	Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. <i>International Journal of Cardiology</i> , 2016, 205, 17-22.	0.8	28
38	Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 85-93.	3.7	38
39	Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1844-1859.	1.1	17

#	ARTICLE	IF	CITATIONS
40	Dabigatran Etxilate: A Review in Nonvalvular Atrial Fibrillation. <i>Drugs</i> , 2017, 77, 331-344.	4.9	19
41	Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. <i>Current Medical Research and Opinion</i> , 2017, 33, 1457-1466.	0.9	19
42	The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis. <i>Medical Decision Making</i> , 2017, 37, 894-904.	1.2	18
43	Long-term benefits of education by emergency care nurses at discharge of patients with atrial fibrillation. <i>International Emergency Nursing</i> , 2017, 35, 7-12.	0.6	20
44	Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 167-177.	1.1	40
45	Atrial fibrillation and use of antithrombotic medications in older people: A population-based study. <i>International Journal of Cardiology</i> , 2017, 249, 173-178.	0.8	19
46	Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults â€” a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. <i>BMC Geriatrics</i> , 2017, 17, 223.	1.1	19
47	Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults â€” a systematic review. <i>BMC Geriatrics</i> , 2017, 17, 225.	1.1	10
48	Fibrilaci3n auricular: enfoque para el m3dico no cardi3logo. <i>Iatreia</i> , 2017, 30, 404-422.	0.1	3
49	Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. <i>The Cochrane Library</i> , 2018, 2018, CD008980.	1.5	36
50	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. <i>Europace</i> , 2018, 20, 1-11.	0.7	80
51	Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Nonâ€”Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 338-345.	0.7	8
52	Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. <i>Current Medical Research and Opinion</i> , 2018, 34, 487-498.	0.9	37
53	Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 191.	2.5	37
54	Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e025102.	0.8	10
55	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2018, 49, 2933-2944.	1.0	246
56	A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants. <i>International Journal of Cardiology</i> , 2018, 269, 174-181.	0.8	39
57	Introduction of Non-Vitamin K Antagonist Anticoagulants Strongly Increased the Rate of Anticoagulation in Hospitalized Geriatric Patients with Atrial Fibrillation. <i>Drugs and Aging</i> , 2018, 35, 859-869.	1.3	2

#	ARTICLE	IF	CITATIONS
58	Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use. <i>JAMA Neurology</i> , 2018, 75, 1511.	4.5	24
59	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 16-25.	2.0	28
60	A study to assess a novel automated electrocardiogram technology in screening for atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1383-1389.	0.5	7
61	Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. <i>Current Medical Research and Opinion</i> , 2019, 35, 733-756.	0.9	10
62	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. <i>American Journal of Therapeutics</i> , 2019, 26, e679-e703.	0.5	4
63	A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961989876.	0.7	15
64	Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 1006-1019.	1.5	23
65	Neural network model analysis of consumption expenditure prediction of urban and rural residents based on Lasso regression analysis. <i>Journal of Intelligent and Fuzzy Systems</i> , 2020, 38, 7203-7214.	0.8	1
66	Enterprise ERP system optimization based on deep learning and dynamic fuzzy model. <i>Journal of Intelligent and Fuzzy Systems</i> , 2020, 38, 7119-7131.	0.8	0
67	Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis. <i>BMJ Open</i> , 2020, 10, e033120.	0.8	3
68	Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. <i>Scientific Reports</i> , 2020, 10, 662.	1.6	16
69	Network meta-analysis: Aspirin plus traditional Chinese medicine for stroke prevention in patients with atrial fibrillation. <i>Journal of Herbal Medicine</i> , 2020, 22, 100355.	1.0	2
70	Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related ischemic stroke. <i>Current Medical Research and Opinion</i> , 2021, 37, 357-365.	0.9	5
71	Impact of carotid atherosclerosis in CHA2DS2-VASc-based risk score on predicting ischemic stroke in patients with atrial fibrillation. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 342-351.	0.7	7
72	Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. <i>Current Medical Research and Opinion</i> , 2021, 37, 891-902.	0.9	5
73	Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. <i>Thrombosis Research</i> , 2021, 203, 121-130.	0.8	4
74	Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2021, 71, 429-442.	0.2	2
75	The risk of bleeding minimization with direct oral anticoagulants. <i>Atherothrombosis</i> , 2021, , 106-126.	0.1	0

#	ARTICLE	IF	CITATIONS
76	Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect. PLoS ONE, 2016, 11, e0161864.	1.1	7
77	Comparison of Approaches for Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation: Network Meta-Analyses of Randomized Controlled Trials. PLoS ONE, 2016, 11, e0163608.	1.1	8
78	Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation. Health Technology Assessment, 2020, 24, 1-184.	1.3	11
79	Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain. Journal of Health Economics and Outcomes Research, 2016, 4, 19-34.	0.6	9
80	Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. EuroIntervention, 2017, 13, 371-378.	1.4	56
81	Rapport sur les anticoagulants oraux directs (AOD) (anticoagulation orale « nouveaux »). Tj ETQq1 1 0.784314 rgBT / Overlock 10	0.0	0
82	HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT. Wiadomości Lekarskie, 2020, 73, 2528-2534.	0.1	1
84	Role of maintenance strategies in advanced epithelial ovarian cancer: a systematic review, network meta-analysis and cost-effectiveness analysis protocol. BMJ Open, 2021, 11, e051037.	0.8	0
85	Predictors of in-hospital hemorrhagic complications in patients with atrial fibrillation undergoing transcatheter aortic valve implantation. Kardiologicheskii Vestnik, 2022, 17, 65.	0.1	1
86	Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. BMJ Open, 2022, 12, e056374.	0.8	3
87	Comparative Effectiveness and Safety of Rivaroxaban and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in an Omani Tertiary Care Hospital. Open Cardiovascular Medicine Journal, 2022, 16, .	0.6	0
88	Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol. BMJ Open, 2022, 12, e050558.	0.8	1
89	Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. The Cochrane Library, 2022, 2022, .	1.5	5
90	Stroke pathway " An evidence base for commissioning " An evidence review for NHS England and NHS Improvement. NIHR Open Research, 0, 2, 43.	0.0	2
93	Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency. Advances in Therapy, 2023, 40, 4264-4281.	1.3	1